JOINING TAPA APAC’S BOARD


11


Will your organisation be conducting any consumer awareness communications through your social media handles?


We are looking forward to raising consumers’ awareness through social media, but we are more inclined to pool industry forces to influence consumers since fighting against the manufacturers and distributors of counterfeit drugs is a common challenge in the industry.


‘Counterfeiters do not rest, especially when it comes


to popular items such as health and medical supplies.’


Do you conduct any training sessions for enforcement agencies, such as police and Customs, to help them identify fake medicines?


Yes, we have participated in many training sessions, especially for Customs and MSAs. We prefer to take a proactive approach to communicating with LEAs to ensure we are all on the same page concerning the new dynamics of anti-counterfeiting.


Will your organisation be ready to submit data on counterfeit medicines and the overall impact of counterfeiting to forums like TAPA?


Any data disclosure to external organizations or forums should obey JNJ data privacy regulations. But approved data will definitely be shared with the industrial working group, to compare notes or evaluate the risk, and as part of joint investigation efforts.


Has JNJ implemented any anti-counterfeit technology in its packaging?


Yes, we use different anti-counterfeit technologies and solutions on different JNJ products. The new digitalized solutions have brought some consumer-engaged solutions that give easy access to authenticate products through scanning. They can be our champions to find potential risk in the market. And, furthermore, we regain consumer trust and bring more confidence to the market.


What are the issues at Customs borders for imported counterfeit medicines which have been manufactured in other countries?


From the industry perspective, we observe some counterfeit drugs manufactured in China, India and some other Southeast Asia regions being exported to EMEA. The flow of counterfeit products across borders are easily masked by falsified Customs declarations and multi-layer entities to avoid Customs inspection and investigation.


Do you feel there is a need for new legislation to deter the production of fake medicines?


Definitely. Legislation needs to transform ahead of future risks. But the reality is not so optimistic. In the private sector, we need to bring these new challenges and our suggestions/proposals to policy decision- makers to better govern oncoming risk. Communication is always the key to get mutual understanding and joint success with government agencies.


How can your experience help TAPA Asia Pacific fight organised crime?


I will bring my unique visioning ability to TAPA. I am experienced in many areas related to end-to-end supply chain security and brand protection. My security background, and my supply chain security and physical security expertise, will help to facilitate that innovation and perceptiveness. I can bring to TAPA not only my ideas from my working experience, but my general passion for a better future for supply chains too.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28